This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Dendreon: Provenge Sales $2.8 Million

Updated with stock price, conference call comments.

SEATTLE (TheStreet) -- Dendreon (DNDN) reported second quarter Provenge sales of $2.8 million, the first financial measure of the prostate cancer therapy's commercial launch since it gained U.S. approval in late April.

On average, analysts were expecting Provenge revenue of about $4 million in the quarter, so the prostate cancer therapy's performance fell short of consensus. The black-or-white, win-or-lose nature of Wall Street earnings reports all but requires such a definitive statement.

Yet the Provenge launch isn't typical since Dendreon can't make enough to satisfy patient demand. The company long ago told investors that limited manufacturing capacity would only allow about 2,000 patients to be treated in the first 12 months of the launch.

As a signal that demand for Provenge is strong, the company said sales totaled $5.2 million in July and doctors wrote 500 Provenge prescriptions in the first three months of the drug's launch. Five hundred patients have not yet been treated with Provenge, but the number represents a proxy for future demand and revenue.

The Provenge outlook helped boost Dendreon shares 4% to $35.30 in Tuesday's after-market trading session. Prior to the earnings release, Dendreon closed flat at $33.83.

The U.S. Food and Drug Administration approved Provenge on April 29. Provenge is the first cancer drug approved that works by activating a patient's own immune system to fight the disease. Under the FDA approval, Dendreon markets Provenge as a treatment for men with advanced prostate cancer that has grown resistant to standard hormone treatment.

Despite the supply constraints, investors have been watching Provenge's commercial launch very closely to see how insurance companies react to the drug's $93,000 price tag. Wall Street is also judging Dendreon's ability to manufacture and deliver on time a cancer drug that must be customized for each patient.

On Tuesday's call, Dendreon said 14 of the 15 regional Medicare carriers have communicated in some way their intent to reimburse Provenge. Private insurance carriers are also providing reimbursement. Dendreon shares took a hit recently when the U.S. government agency that oversees the Medicare program announced plans to initiates a national coverage assessment for Provenge.

Dendreon also reiterated that expansion of the three Provenge manufacturing facilities are on track to bring supply up to full capacity in the middle of 2011.

Dendreon launched Provenge in May so the company reported less than a quarter's worth of sales Tuesday. Expectations, however, only ramp up from here. At present, consensus Provenge sales are $23 million in the current quarter and $44 million in the fourth quarter. Next year, Wall Street is looking for Provenge sales topping $360 million.

Also Tuesday, Dendreon reported a net loss of $142.6 million, or $1.04 a share, below with Wall Street's consensus forecast.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,915.07 -70.54 -0.42%
S&P 500 1,964.68 -8.15 -0.41%
NASDAQ 4,396.2040 -22.83 -0.52%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs